MWA
AVDL

MFA Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

MFA Wealth Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-950
Closed -$12.5K – 98
2024
Q3 		$12.5K Hold
950
– – ﹤0.01% 309
2024
Q2 		$13.4K Buy
+950
New +$15.5K ﹤0.01% 303

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

MFA Wealth Advisors's AVDL Position: Q4 2024 in Review

MFA Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 950 shares — an estimated $12.5K sold.

MFA Wealth Advisors first reported a position in AVDL in Q2 2024 and held it in 2 quarters. The position peaked at $13.4K in Q2 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • MFA Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • MFA Wealth Advisors sold 950 Avadel Pharmaceuticals shares in Q4 2024, an estimated $12.5K.
  • MFA Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • MFA Wealth Advisors's Avadel Pharmaceuticals position peaked at $13.4K in Q2 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on MFA Wealth Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.